Literature DB >> 1903673

Soluble interleukin-2 receptor and soluble CD8 antigen levels in serum from patients with non-resectable lung cancer.

J Vibe-Petersen1, N Tvede, M Diamant, A A Kjerulff, H R Sørensen, V Andersen.   

Abstract

In a preliminary longitudinal study two women with histologically verified adenocarcinoma of the lung, without simultaneous infectious or inflammatory conditions, were seen every 2 weeks until death. In one of the patients serum soluble interleukin-2 receptor (sIL-2R) levels rose progressively while the levels for the other patient increased during the second half of the observation period. Serum soluble CD8 antigen (sCD8 Ag) showed a pattern dissimilar to the one for sIL-2R. In a retrospective cross-sectional study circulating levels of sIL-2R and sCD8 Ag were measured before explorative thoracotomy in a total of 65 patients with histologically proven non-resectable carcinoma of the lung. The sIL-2R levels were significantly increased independently of histological subclassification while sCD8 Ag was increased only in patients with small-cell lung cancer. There was no correlation between pre-operative values and length of survival.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1903673     DOI: 10.1007/bf01742540

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  27 in total

Review 1.  The interleukin 2 receptor.

Authors:  K A Smith
Journal:  Annu Rev Cell Biol       Date:  1989

Review 2.  Serum interleukin-2 receptor: clinical and biological implications.

Authors:  C H Pui
Journal:  Leukemia       Date:  1989-05       Impact factor: 11.528

3.  Soluble CD8 during T cell activation.

Authors:  B E Tomkinson; M C Brown; S H Ip; S Carrabis; J L Sullivan
Journal:  J Immunol       Date:  1989-04-01       Impact factor: 5.422

Review 4.  Suppressor cell function in solid tumor cancer patients.

Authors:  J Von Roenn; J E Harris; D P Braun
Journal:  J Clin Oncol       Date:  1987-01       Impact factor: 44.544

Review 5.  The soluble interleukin-2 receptor in haematological disorders.

Authors:  G Pizzolo; M Chilosi; G Semenzato
Journal:  Br J Haematol       Date:  1987-12       Impact factor: 6.998

6.  The natural five-year course in bronchial carcinoma. Epidemiologic results.

Authors:  E Nõu
Journal:  Cancer       Date:  1984-05-15       Impact factor: 6.860

7.  Lung natural killer and interleukin-2 activity in lung cancer. A pulmonary compartment of augmented natural killer activity occurs in patients with bronchogenic carcinoma.

Authors:  A E Pitchenik; J Guffee; J Stein-Streilein
Journal:  Am Rev Respir Dis       Date:  1987-12

8.  Plasma interleukin-2 and a soluble/shed interleukin-2 receptor in serum of patients with Crohn's disease. Effect of cyclosporin.

Authors:  J Brynskov; N Tvede
Journal:  Gut       Date:  1990-07       Impact factor: 23.059

9.  Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro.

Authors:  L A Rubin; C C Kurman; M E Fritz; W E Biddison; B Boutin; R Yarchoan; D L Nelson
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422

10.  Expression of interleukin 2 receptors on activated human B cells.

Authors:  T A Waldmann; C K Goldman; R J Robb; J M Depper; W J Leonard; S O Sharrow; K F Bongiovanni; S J Korsmeyer; W C Greene
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

View more
  1 in total

1.  Circulating immune markers in advanced renal cell carcinoma during immunotherapy with interferon gamma.

Authors:  K Höbarth; A Hallas; G Steiner; A Gomahr; W Aulitzky; M Marberger
Journal:  Urol Res       Date:  1996
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.